The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration - Top-Institutions - MDSpire

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

  • By

  • Aleksander Dominikowski

  • Zofia Rękoś

  • Michał Olejarz

  • Ewelina Szczepanek-Parulska

  • Remigiusz Domin

  • Marek RuchaŁa

  • June 18, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Endocrinology
    • Diabetes

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Endocrinology
    • Diabetes

Original Source(s)

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

  • by Aleksander Dominikowski, Zofia Rękoś, Michał Olejarz, Ewelina Szczepanek-Parulska, Remigiusz Domin, Marek RuchaŁa

  • June 18, 2026

Related Content

Editorial: Association of diabetes mellitus with cognitive impairment and neurological disorders, volume II

Analysis of metabolites in serum and villous tissue of missed abortion patients based on targeted metabolomics

The difference in scotopic and photopic pupil responses: a potential indicator for long-term glycemic management